Hypercalcemia associated with primary mucinous ovarian tumor followed by pseudomyxoma peritonei can be fatal: a case report

Hypercalcemia is a common complication of malignancy, occurring in up to 30% of patients. The development of hypercalcemia in patients with cancer portends a worse prognosis, with patients more likely to have advanced disease and decreased survival rates. Mucinous neoplasms of the ovary account for 10%–15% of ovarian neoplasms. They may be benign, borderline, or malignant. The majority are benign or borderline, accounting for 80% and 16%–17%, respectively. Pseudomyxoma peritonei (PMP) is a rare disease. It refers that PMP is the accumulation of mucin in the abdominal or pelvic cavity derived from associated mucinous tumor usually from the appendix, but also associated with ovarian mucinous tumors. Herein, we report a case of hypercalcemia associated with primary mucinous ovarian tumor followed by PMP that had fatal consequences.

Hypercalcemia; Mucinous ovarian tumor; Pseudomyxoma peritonei.

[1] Goldner W.: “Cancer-Related Hypercalcemia”. Journal of Oncology Practice, 2016, 12, 426-432.

[2] Stewart A.F.: “Hypercalcemia Associated with Cancer”. N. Engl. J. Med., 2005, 352, 373-379.

[3] Ma X.G., Wang Y.M., Zhang X.H., Dong M.T., Yang W., Xue F. X.: ”Ovarian cancer presenting with hypercalcemia: two cases with similar manifastations but different mechanisms”. Cancer Biol Med., 2018, 15, 182-187.

[4] Xuegong M., Yingmei W., Xuhong Z., Mengting D., Wen Y., Xue F. X.: “Ovarian cancer presenting with hypercalcemia: two cases with similar manifestations but different mechanisms”. Cancer Biology & Medicine, 2018, 15, 182.

[5] Qu Z.: “Management of pseudomyxoma peritonei”. World J. Gastroenterol., 2006, 12, 6124.

[6] Lieske B., Moran B.: “Pseudomyxoma peritonei”. Intraperitoneal Cancer Therapy, 2015, 225-234.

[7] Faris J.E., Ryan D.P.: “Controversy and Consensus on the Manage-ment of Patients With Pseudomyxoma Peritonei”. Curr. Treat. Options Oncol., 2013, 14, 365-373.

[8] Santarpia L., Koch C.A., Sarlis N. J.: “Hypercalcemia in Cancer Patients: Pathobiology and Management”. Horm. Metab. Res., 2010, 42, 153-164.

[9] Baird G.S.: “Ionized calcium”. Clin. Chim. Acta, 2011, 412, 696-701.

[10] Mundy G.R., Edwards J.R.: “PTH-Related Peptide (PTHrP) in Hypercalcemia”. J. am. Soc. Nephrol., 2008, 19, 672-675.

[11] Reagan P., Pani A., Rosner M. H.: “Approach to Diagnosis and Treatment of Hypercalcemia in a Patient With Malignancy”. am. J. Kidney Dis., 2014, 63, 141-147.

[12] Schwartz G.G., Skinner H.G.: “Prospective studies of total and ion-ized serum calcium in relation to incident and fatal ovarian cancer”. Gynecol. Oncol., 2013, 129, 169-172.

[13] Shen X., Mula R.V.R., Evers B.M., Falzon M.: “Increased cell survival, migration, invasion, and Akt expression in PTHrP-overexpressing LoVo colon cancer cell lines”. Regul. Pept., 2007, 141, 61-72.

[14] Morera-Ocon F.J., Navarro-Campoy C.: “History of pseudomyx-oma peritonei from its origin to the first decades of the twenty-first century”. World J Gastrointest Surg, 2019, 11, 358-364.